M. Negru

A10.06 Detecting adalimumab serum level and anti-drug antibodies – future tool in monitoring spondyloarthritis patients?

Background and objectives Anti-TNF agents have highly proved their efficacy in spondylarthritis (SpA) patients, with a good rate of response of approximately 70%. However a third of patients lose response to treatment. Measuring the drug serum level and anti-drug antibodies might lead to identifying the cause of non-response, followed by adjusting the therapeutic scheme. The aim was to determine the utility of determining drug serum adalimumab (ADL) and anti-ADL antibodies in assessing disease activity in SpA patients. Methods Over a period of 11 months we included 54 SpA patients on ADL, with further exclusion of those who had delayed drug administration or suffered a concomitant infection. Demographic, clinical (disease activity scores) and laboratory (ESR, CRP) data were collected. We measured the determination of interest using Promonitor kits, using the ELISA technique and the statistical analysis was performed with SPSS 20.0. Results Out of the total 35 patients, 74% were males, the mean age was 40 years old with a mean disease duration of 102 months. HLA B27 was positive in 91% of patients and 28% required sacroiliac joint MRI at diagnosis, being a non-radiographic form. 28% of patients tested positive for Quantiferon and underwent chemoprophylaxis. 22% had history of uveitis before diagnosis and 9% had recurrences while on ADL. 82% of patients had detectable ADL levels. The BASDAI score was significantly higher in patients with undetectable ADL (P < 0.001), with a mean value of 6.3 indicating an inadequate disease control. Furthermore, both ASDAS-ESR and ASDAS-CRP were higher in these patients (P < 0.001). 25% had positive anti-ADL antibodies. Patients with no identified antibodies had lower disease activity scores (BASDAI, ASDAS-VSH and ASDAS-CRP, P < 0.001). Acute phase reactants (ESR, CRP) had a higher value in patients with positive anti-ADL antibodies (P = 0.015 and P < 0.001, respectively). Serum level ADL negatively correlated to the presence of anti-ADL antibodies (r = -0.360, P = 0.034) and to disease activity scores. Conclusions Undetectable serum drug level together with the presence of anti-drug antibodies and the increase of SpA activity scores indicate the impact of immunogenicity throughout secondary non-responder patients. Prompt identification of these patients might lead to a better adapted therapeutic scheme.

AB1158 Prevalence of comorbidities in psoriatic arthritis: a cross-sectional study

Background Psoriatic arthritis (PsA) is associated with important comorbidities: cardiovascular, gastro-intestinal, infectious, malignant, and psychiatric [1, 2]. However, they are less studied in PsA compared to other chronic inflammatory arthritis. Objectives The objective of this study was to calculate the prevalence of comorbidities and risk factors in a cohort of PsA patients. Methods This was an observational cross-sectional study, including consecutive, unselected adult patients, with a diagnosis of PsA according to their rheumatologist. Data collected: demographical, clinical (affected joints, current psoriasis, axial involvement, enthesitis, dactylitis), biological (acute phase reactants), and treatment related (nonsteroidal anti-inflammatory drugs, synthetic remissive drugs and biologics). Data on comorbidities and risk factors were collected according to the European League Against Rheumatism (EULAR) recommendations on reporting comorbidities in chronic inflammatory rheumatic diseases in daily practice [3]. Results In all, 129 PsA patients were included: 77 (59.7%) women, mean age ± standard deviation 53.5±11.8 years, disease duration 7±7.4 years; 53 (41.1%) had axial involvement, 33 (25.6%) dactylitis, 18 (14%) enthesitis, and 24 (18.6%) current moderate/severe psoriasis. Most of them had low or moderate disease activity and almost a quarter of them (32; 24.8%) were taking a biologic. The most prevalent comorbidities were: dyslipidaemia 103 patients (79.8%), hypertension 67 (51.9%), obesity 44 (34.1%), diabetes 21 (16.3%) and ischemic heart disease 15 (11.6%). Almost a third of patients (42, 32.6%) suffered a cardiovascular event after their PsA diagnosis, of which heart attack 2 patients, stroke 4, cardiac failure 4 and peripheral arterial disease one patient. Cardiovascular events correlated with smoking (r=0.893, p<0.001) and current moderate/severe psoriasis (r=0.218, p=0.013). Regarding infectious comorbidities: 11 patients (8.5%) had a history of tuberculosis after being diagnosed with PsA, 7 (5.4%) chronic viral hepatitis, of which 4 with B virus and 3 with C virus, and 5 patients (3.9%) developed severe infections. Five patients (3.9%) were diagnosed with neoplasia, but no correlation was identified with any of the clinical, biological or treatment related included variables. Only 11 patients (8.5%) were diagnosed with depression, but the prevalence is probably underestimated, since not all patients were screened to this end. Conclusions PsA is associated with a high prevalence of comorbidities, especially cardiovascular diseases. This should be taken into consideration in the therapeutic and the global management of PsA patients. References Husni ME, Mease PJ. Managing comorbid disease in patients with psoriatic arthritis. Curr Rheumatol Rep 2010;12(4):281–7. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: apopulation-based cohort study. Ann Rheum Dis 2015;74(2):326–32. Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Ann Rheum Dis 2016;75(6):965–73. Disclosure of Interest None declared

A10.05 Optimising existing tools for reaching an adequate disease control in patients with spondylarthritis

Background and objectives Disease activity in spondylarthritis (SpA) is widely evaluated through disease activity scores such as BASDAI, ASDAS and PtGA, with no proven superiority between them. The aim of this study was to subdivide patients with anti-TNF therapy according to their disease status indicated by scores in order to evaluate group characteristics with further assessment on the quality of each activity indicator. Materials and methods We included 100 SpA patients under anti-TNF therapy (32 infliximab, 33 adalimumab, 35 etanercept). We collected demographic, clinical (BASDAI, ASDAS, PtGA) and laboratory (ESR, CRP) data. Statistical analysis was performed with SPSS 20.0. Results We evaluated disease activity for the entire study group based on conventional scores: BASDAI, ASDAS-CRP, ASDAS-ESR, acute phase reactants and PtGA. When used as an external criterion PtGA showed that 12% of patients had active disease while 88% were classified as low disease activity (PtGA < 5). Mean ASDAS-CRP/ESR in the active group were 3.39/3.24. Mean BASDAI score in the high activity group was 5.66. We showed that both ASDAS scores had good discriminating capacities, with similar values when using the SMD (ASDAS-CRP and ASDAS-ESR – SMD 2.00). In our study group, based on PtGA, BASDAI outperformed ASDAS scores with a SMD of 3.33. We used ROC curves of the disease activity scores by using the PtGA ≥ 5 as variable of high disease activity state. For ASDAS-CRP, ASDAS-ESR and BASDAI the AUCs (area under curve) were 0.89 (P = 0.05), 0.88 (P < 0.001), and 0.99 (P = 0.009), respectively. For CRP and ESR the AUCs were 0.81 and 0.79 (P = 0.001, P = 0.003). This shows the high accuracy of the three scores in assessing SpA activity. When dividing patients according to BASDAI score (4 as cut-off), 14% showed a more active disease than the rest of 86% who had low disease activity. Mean ASDAS scores in the first group were 3.31 and 3.16, respectively. BASDAI correlated to both ASDAS scores (r = 0.65 and 0.71, P < 0.001) and PtGA stronger to BASDAI(r = 0.912, P < 0.01) than ASDAS(r = 0.67 and 0.71, P < 0.01). Conclusion We proved that disease activity scores have good discriminatory power and that BASDAI and ASDAS perform similarly in assessing and investigating SpA patients. BASDAI outperformed ASDAS when using PtGA as criterion.

FRI0256 Significance of Cognitive Impairment in Systemic Sclerosis

Background There is an increased appreciation of the burden of cognitive impairment in people with autoimmune diseases (1). Recent studies have demonstrated that patients with systemic sclerosis (SSc) have a specific pattern of cognitive impairment: the dysexecutive syndrome (2). Objectives We evaluated the prevalence of cognitive impairment in SSc and assessed the association with the disease features and impact on daily living Methods Consecutive SSc from EUSTAR center 096 were examined. Montreal Cognitive Assessment (MoCA) was used to assess cognitive dysfunction and scores ≤26 were considered abnormal (3). SSc patients were assessed according tu MEDS evaluation sheets to determine organ involvement, autoantibody profile, disease activity (Valentine Activity Index) and disease severity (Medsger Severity Index). sHAQ (Scleroderma Health Assessment Questionnaire) has also been completed. Data were compared by difference tests according to the types of variables: t-test, Mann-Whitney or chi-square. To evaluate correlations between variables Pearson or Spearman correlations were used. Results A total of 70 SSc patients [36 (51.42%) limited SSc (lSSc) and 34 (48.57%) with diffuse SSc (dSSc), 60 female; mean age 54.5 (±11.62) years; mean disease duration 66 (±429.6) months] were included in the study. 47.14% of the patients had active disease, the mean Rodnan score was 7 (±4.17), the mean Medsger score was 5.5 (±2.89), 24.28% of the patients had lung involvement and 20% had pulmonary arterial hypertension. The mean HAQ was 1 (±0.59). Cognitive impairment was identified in 65.71% SSc patients; the mean MOCA score was 26 (±2.83). Cognitive impairment of SSc patients was related to older age (r=-0.378, p=0.001), rural provenience (r=-0.351,p=0.003), severity of the disease evaluated by the Medsger score (r=–0.262,p=0.029) and poor quality of life evaluated by sHAQ (r=-0.323,p=0.003).Correlations were also identified with musculoarticular involvement (r=-0.330,p=0.006), advanced capillaroscopy patttern (r=-0.331, p=0.006). The diiffuse SSc patients were more likely to have cognitive dysfunction (likehood ratio 0.012) as were those with SCL70 positive (0.0.18). No relationship was identified between cognitive impairment and lung, heart or renal involvement, the presence of digital ulcers, the use of corticosteoids or immunosuppression. Conclusions An increased prevalence of cognitive impairment was observed in SSc and associated with age, rural provenience, more severe disease, muscle involvement and poor quality of life. Further studies are needed to be compared with healthy controls and to assess the role of microvascular damage or that of other confounders. References T.N.Amaral et al. Prevalence and significance of cognitive impairment in systemic sclerosis Ann Rheum Dis 2015;74:605 Ylmaz N. et al Dysexecutive syndrome: a specific pattern of cognitive impairment in systemic sclerosis Cogn Behav Neurol. 2012 Jun;25(2):57–62. www.mocatest.org/normative-data/ Disclosure of Interest None declared

A5.4 Prevalence of comorbidities in Paget’s disease of the bone a single centre report

Background and objectives Paget disease (PD), also known as osteitis deformans, is characterised by single or multiple bone site alteration, including accelerated osteoclast-mediated resorption followed by increased low quality bone production. This process results in a disorganised, unsteady structure that may lead to bone deformity. This condition affects elderly adult population, with a slightly higher predominance in males and it is thought to have important genetic determinants. The association of comorbid conditions places a burden on the patients and imposes regular monitoring. The present study aims to evaluate associated medical conditions in patients suffering from PD. Methods We retrospectively identified 39 patients who were diagnosed with PD, based on clinical presentation, plain x-rays, scintigraphy or when necessary biopsy or bone turnover markers’ detection. For the study group we noted the presence of cardiovascular disorders – hypertension, ischaemic heart disease or rhythm abnormalities such as atrial fibrillation. Median body mass index (BMI) was calculated. Neurologic conditions namely hearing loss, Parkinson’s disease or cerebral stroke history were taken into account, as well as type 2 diabetes and prostate adenoma. Tobacco use was also assessed for the study group. Development of neoplasia was reviewed. Information was gathered from patients’ clinical charts over a period of one year. Results Out of the 39 patients included in the study lot, 64.1% were males and 35.9% of female gender (1.7:1 ratio) with a mean age of 65.67 years, who were mainly diagnosed on the basis of clinical and radiographic assessment (97.4%). 7.6% had positive family history of PD. The polyostotic form of PD encountered in 26 patients (66%) is prevalent over the monostotic pattern (13, 33.3%). The most common affected sites were the hip in 71.0% of patients, skull (44.7%), femoral bone (26.3%) and the lumbar spine (21.05%). 61.5% of patients were hypertensive while 28.2% associated ischaemic heart disease. 27.6% were priorly diagnosed with atrial fibrillation. Mean BMI value was calculated at 27.7 kg/m². 12.8% of patients were hypoacusic, 5.1% suffered from a cerebral stroke and the same percentage were diagnosed with Parkinson’s disease. 52% of males had prostate adenoma, 15.3% suffered from type 2 diabetes. 20.5% patients confirmed smoking status. Three patients developed neoplasia, namely squamous cell carcinoma, carcinoma of the breast and rectum with no correlation to disease duration. Conclusions Taking into consideration the difficulties that PD brings with it, associated comorbidities tend to diminish further the health and quality of life in these patients. Therefore a complete medical check-up is recommended on each follow up visit in order to improve their status.

A5.6 Muscular weakness and pain in patients with rheumatoid arthritis - correlations with electromyography, clinical and serological data

Background and objectives Muscular involvement (mostly by weakness, pain and fatigue) is frequently involved in rheumatological practice. Associated myopathy to rheumatoid arthritis (RA) is an important comorbity that causes supplementary disability. Our objectives are to investigate the muscular involvement in RA with electromyography (amplitude, duration and motor unit potential MUP) and to correlate the data with clinical and laboratory findings. Material and methods Consecutive patients with RA, weakness and muscle pain were recruited during a 9 month period. Clinical (VAS, muscular testing, 6 min walk test) and laboratory tests (creatinkinase, dehydrogenase lactate, inflammatory markers, vitamin D serological level) were performed. The electromyographic study was pursued with concentric needle for MUP evaluation, then amplitude, duration and polyphasic pattern at deltoid muscle, interosseous, vastus lateralis and anterior tibial muscle were registered. Results 50 patients (88% women, mean age 62.8 +/-11.5 years) diagnosed with PR and muscle weakness were included. Clinically, DAS 28 (mean 3.76+/-1.44), HAQ (mean 1.49+/-1.12), VAS scale pain (mean 5.18+/-2.5), time up and go test (mean 12.62+/-5.78 min) and 6 min walk test (mean 277.306+/-153.34 metres) were reported. DAS 28 correlates positively with serological levels of creatinkinase (0.768, p < 0.00), C reactive protein (0.421, p < 0.00) and vitamin D level (0.871, p < 0.00) also with polyphasic pattern at deltoid level and duration of MUP in vastus lateralis muscle (0.768, p < 0.00). Polyphasic pattern in the upper limb is related to a similar pattern in lower limb muscles (0.510, p < 0.00). Lower duration of action potential was found in: deltoid (64% of cases), anterior tibial (58%), interosseous (44%) and vastus lateralis muscle (36%). Conclusion Associated myopathy to RA affects quality of life and function impairment in upper and lower limbs. DAS 28 correlates also with myopathic involvement and vitamin D levels in patients with RA. Most affected muscles are deltoid and anterior tibial muscle. Both upper and lower limbs muscles showed similar polyphasic pattern on electromyography.

FRI0473 Is Male Sex a Negative Predictor for Systemic Sclerosis? Experience of a Eustar Center

Background Systemic sclerosis (SSc) has a female predominance, however, little is understood about the effect of sex on SSc manifestations and survival. Objectives The objectives of our study were to evaluate differences in disease manifestations, and survival rates between males and females with SSc. Methods A retrospective cohort study of EUSTAR center 096 was conducted to evaluate sex-based differences in disease manifestations and survival. A complete baseline evaluation of all patients was done according to MEDS evaluation sheets. A complete follow-up was done every year. All calculations were performed with SPSS Statistics 20.0. Student t-test or Mann-Whitney test and chi-square test were used to evaluate differences for variables. Pearsons bivariate correlation or Spearmans rank correlation coefficient were used to evaluate the association between evaluated variables. The values of r>0.5 and p<0.05 were considered statistically significant. Results 90 SSc patients (82 females and 8 males) were followed between JAN 2010 – JAN 2015, with a female:male ratio of 10,25:1. Male patients with systemic sclerosis are younger (48.63±13.46 years compared to 55.63±11.51 years in females), have a shorter disease duration (76±78.13 months compared to 124.11±86.6 months in females), higher Rodnan skin scores (12.38±7.46 compared to 8.85±5.14 in females) with more frequent diffuse skin involvement (62,5% compared to 52,38% in females), develop more frequent digital ulcers (50% compared to 40,29% in females), pulmonary fibrosis (62,5% compared to 35,82% in females), pulmonary arterial hypertension (37,5% compared to 17,91% in females) and have higher Medsger severity score (8.75±3.28 compared to 6.87±3.06); yet none of the above reached statistical significance. Still, activity score seems to be higher in male patients (5,62±3,00 compared to 3,53±1,87, p=0,007). Mortality rates at 5 years was 50% for men compared to 8,95% for women, close to statistical significance (p=0,061). Male sex was associated with increased risk of scleroderma renal crisis (p=0.001). Conclusions The differential effect of disease between sexes is small, yet males have increased risk of scleroderma renal crisis compared to females with SSc. References Hussein H, Lee P, Chau C, Johnson SR. The effect of male sex on survival in systemic sclerosis.J Rheumatol. 2014;41(11):2193-200 Disclosure of Interest None declared

AB0710 Causes and Risk Factors for Death in Systemic Sclerosis – Experience of a Eustar Center

Background Systemic sclerosis (SSc) has a case-based mortality that is one of the highest among the rheumatic diseases. Objectives To identity predictors of mortality in patients with systemic sclerosis from their first evaluation in a reference center Methods 90 SSc patients were followed between JAN 2010 – JAN 2015. A complete baseline evaluation of all patients was done according to MEDS evaluation sheets (demographics, disease history, main organ involvement). A complete follow-up was done every year. Univariate and multivariate predictors of survival were assessed using proportional hazards regression modelling Results Amongst the cohort of 90 patients the mean age at diagnosis was 55,65 (SD 12,45) years, medium disease duration was 11,7 (SD 6,9) years. Medium disease activity score was 3,43 (SD 2,14) years. In the deceased group (10 patients), the mean age of death was 43,7 years (SD 8,9 years). The 5- year survival rate at was 88,88%. The most common cause of SSc-related mortality was pulmonary complications (60%). 70% of deaths were attributed directly to SSc. Of the SSc-related deaths, 28,57% were attributed to pulmonary fibrosis, 57,14% to pulmonary arterial hypertension (PAH) and 14,28% to cardiac causes (arrhythmias). Among the non-SSc-related causes, infections (33%) and malignancies (33%) were followed by indidental causes (33%). Sex- and age-adjusted univariate analysis identified the diffuse subset, a modified Rodnan score (mRSS)>14, pulmonary fibrosis, pulmonary hypertension, scleroderma renal crisis and a Medsger score>10 to be associated with increased mortality in all patients. Sex- and age-adjusted multivariate model identified a mRSS >14 OR 1,562 [1.00; 2.42] and pulmonary hypertension OR 1.336 [1.03; 1.73] as predictors of death. Conclusions Disease-related causes, in particular pulmonary hypertension and pulmonary fibrosis accounted for the majority of deaths in SSc. Mortality rate in the center seems to be a little bit higher than the EUSTAR cohort, especially in patients with pulmonary hypertension possibly related to difficult acces to specific vasodilator treatment. Higher Rodnan skin scores at baseline evaluation still remains an important mortality predictor. References Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol. 2014;26(2):131-7 Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.Ann Rheum Dis. 2010 Oct;69(10):1809-1 Disclosure of Interest None declared

AB1072 The Assessment of Myopathy in Rheumatoid Arthritis – Vitamin D Status and Clinico-Biological and Electromyography Correlations

Background Muscle damage is one of the least studied elements of the extra-skeletal manifestations of RA. Objectives The evaluation of vitamin D levels in a group of patients with RA and clinical myopathy and establishing correlations with clinical and electromyographic muscle activity indices. Methods We prospectively evaluated 50 patients with rheumatoid arthritis and myopathy and 21 healthy subjects, admitted in the Rheumatology Department of “St.Maria” Hospital between September 2013 and October 2014. Electromyographic exams were performed on all the patients in the active group, as well as on 11 subjects in the control group, who had consented to this procedure. I used the concentric needle method for recording MUP and quantitative analysis of multi-MUP. Vitamin D was assessed by measuring the serum level of 25(OH) vitamin D, using the Elisa methode. I focused on EMG correlation with the serum levels of vitamin D and the validated parameters of muscle testing (MRC force testing, chair rising test, TUG, TGT), titre of specific muscle enzymes or acute phase reactants, DAS28/HAQ. The analysis of the differences in distribution between the active group and the control group was made by Kruskal-Wallis test. Statistical correlations were tested by Pearson test. Results The active group had an average age of 62.80 (11.51) years. The predominance of the female sex is noteworthy: the F/M ratio was 22:3 in the active group and 3.2:1 in the control group. The average serum levels of vitamin D in the active group were 28.94 (14.23) ng/ml; 28% of the subjects fit into insufficiency and 32% in the category of deficiency. In the control group, the average serum level of vitamin D was 31.96 (24.92), predominantly (52%) with deficiency. There was no statistically significant difference between the groups (p>0.05). In both groups, serum levels of vitamin D were significantly (p<0.05) higher in subjects whose blood samples had been collected in summer, as opposed to those whose blood had been sampled during winter. The percentage of subjects with values considered optimal was similar. The average duration of the disease in the active group was 12.68 (8.89) years and the average value of the disease activity score (DAS28) was 3.76 (1.44), 56% of patients with RA having a moderate or highly active form of the disease. EMG changes were better expressed in the active group with rheumatoid myopathy compared to the control group, especially for the studied parameters of the upper limb. 32 patients with RA had a short, myopathic duration of MUPs deltoid muscle and a myopathic duration in the first dorsal interosseous muscle was present at 22 patients. In the RA group, 27 patients had a complete, full interference pattern. The serum level of vitamin D was correlated with the clinical parameters for testing muscle weakness. Conclusions The electromyographic changes more evident in the upper limb describe an inflammatory component of myopathy in RA, while predominant lower limb muscle damage has cortisone etiology. Lower limb muscle damage may be an indicator of myopathy in rheumatoid arthritis, related to the vitamin D level. References Kimura J., Myopathies” in Neuromuscular junction, muscle disease and abnormal muscle activity”, ed. 4: Oxford Univeristy Press, 2013: 841-889. Disclosure of Interest None declared

AB1224-HPR Type of Personality – a New Item to Take into Account When Evaluating Quality of Life and Disease Activity in Rheumatoid Arthritis (RA) Patients

Background In RA pts, health-related quality of life (HRQoL) assessment is important, but there is little research regarding the relation between the type of personality and the individual differences in HRQoL1. Optimism and the tendency to hold greater positive outcome expectancies have been found to be related with better psychological well-being in RA pts, while negative affectivity (components of type C and D personality) are reported to show lower health satisfaction scores2. Objectives The aim of the present study was to investigate the association of different types of personality with aspects of HRQoL and disease activity in RA pts. Methods This cross-sectional study included 104 RA pts from two different Rheumatology Departments (7.7% men, 92.3% women, mean age 59.08, mean duration of disease 12.77 years). Personality type was assessed with Jenkins Activity Survey for type A/B, State-Trait Anger Expression Inventory Anger-in Scale (AIS) for type C and Type D Personality Scale (DS14), with its components (negative affect-NA and social inhibition-SI) for type D. HRQoL was quantified using the Medical Outcome Study Short-Term-36 (SF36v2) and its subscales (Physical function-PF, Social function-SF, Role physical-RP, Role emotional-RE, Mental health-MH, Vitality-VT, Bodily Pain-BP, Global Health-GH, physical component scores-PCS and mental component scores-MCS). Disease activity was evaluated with Disease Activity Score (DAS28) and visual analog scale (VAS) for pain. Results Type C pts correlate with decreases in HRQoL in 7 of its 8 subscales when compared to non-C personality pts (RP M=15±28.56/M=3.14±38, VT M=32.57±2.23/M=44.63±22.68, RE M=27.62±39.18/M=49.99±44.05, MH M=39.54±25.88/M=62.64±22.44, MCS M=36.98±13.33/M=46.52±12.36; p<0,05), whereas type D pts show lower values only in 5 of 8 components when compared to non-D (RP M=4.68±1/M=29.06±37.54, GH M=28.75±13.6/M=38.63±23.99, VT M=25±17.88/M=43.83±21.93, SF M=49.21±27.18/M=63.6±25.18, RE M=8.33±19.24/M=49.22±43.9, MH M=26.75±22.75/M=6.51±22.71, MCS M=29.89±11.17/M=45.98±12.22; p<0,05). Less features of type C associate with better MH (r=-.58) and less type D traits (smaller the NA and SI) with better MCS (rNA=-.55, rSI=-.38). Type C and D pts also have increased disease activity levels, not only related to DAS28, but also to PGA. Type A pts assess pain by VAS to be lower than those with type B (M=56.5±34.94 vs 84.66±15.09, p<0,05), with no other significant correlations. Conclusions The present study showed associations between type C and D personalities with negative effects on several components of HRQoL in RA pts and also with higher disease activity. We did not find significant correlations with type A personality, except for a lower pain assessment. Future research including prospective follow-up assessments is needed in order to determine if the personality type influences the evolution of disease and the response to treatment in RA patients. References Uhlig T., et al. Rheumatology. 2007;34(6):1241-1247. Treharne GJ, et al. Br J Health Psychol.2007;12(1):323–345. Disclosure of Interest None declared